A
Abraham M. Varghese
Researcher at St James's University Hospital
Publications - 27
Citations - 555
Abraham M. Varghese is an academic researcher from St James's University Hospital. The author has contributed to research in topics: Minimal residual disease & Fludarabine. The author has an hindex of 12, co-authored 27 publications receiving 491 citations. Previous affiliations of Abraham M. Varghese include Hull Royal Infirmary & Leeds Teaching Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study
Peter Hillmen,John G. Gribben,George A Follows,Donald Milligan,Hazem A. Sayala,Paul Moreton,David Oscier,Claire Dearden,Daniel B. Kennedy,Andrew R. Pettitt,Amit Nathwani,Abraham M. Varghese,Dena Cohen,Andy C. Rawstron,Stephan Oertel,Christopher Pocock +15 more
TL;DR: R-chlorambucil may improve outcome for patients who are ineligible for fludarabine-based treatments, suggesting that the addition of rituximab to chlorambucin may improve efficacy with no unexpected adverse events.
Journal ArticleDOI
Minimal residual disease is an independent predictor for 10-year survival in CLL
Marwan Kwok,Marwan Kwok,Andy C. Rawstron,Abraham M. Varghese,Paul Evans,Sheila J.M. O’Connor,Chi Doughty,Darren J. Newton,Paul Moreton,Peter Hillmen +9 more
TL;DR: The results demonstrate the long-term benefit of achieving MRD negativity, regardless of the therapeutic setting and treatment modality, and support its use as a prognostic marker for long- term PFS and as a potential therapeutic goal in CLL.
Journal ArticleDOI
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
Peter Hillmen,Dena Cohen,Kim Cocks,Andrew R. Pettitt,Hazem A. Sayala,Andy C. Rawstron,Andy C. Rawstron,Daniel B. Kennedy,Christopher Fegan,Don Milligan,John Radford,Jane Mercieca,Claire Dearden,Raphael Ezekwisili,Alexandra Smith,Julia Brown,G. Booth,Abraham M. Varghese,Christopher Pocock +18 more
TL;DR: The addition of rituximab to FCM improves the response rates in relapsed CLL, resulting in more complete remissions and without additional safety concerns, and should be fully tested in a randomized Phase III trial.
Journal ArticleDOI
Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia
TL;DR: Persistent monoclonal plasma cells were readily identified by CD138 immunohistochemistry, explaining the persistence of serum M protein in patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma.
Journal ArticleDOI
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
Christopher Parrish,Gina B. Scott,Gemma Migneco,Karen Scott,Lynette Steele,Elizabeth Ilett,Emma West,Kathryn Hall,Peter Selby,D Buchanan,Abraham M. Varghese,Mark S. Cragg,Matthew C. Coffey,Peter Hillmen,Alan Melcher,Fiona Errington-Mais +15 more
TL;DR: It is demonstrated that reovirus is directly cytotoxic against CLL, which requires replication-competent virus, and phenotypically and functionally activates patient NK cells via a monocyte-derived interferon-α (IFNα)-dependent mechanism, and enhances ADCC-mediated killing of CLL in combination with anti-CD20 antibodies.